ARTICLE | Clinical News
SB-435495: Phase I
March 5, 2001 8:00 AM UTC
Human Genome Sciences Inc. (HGSI, Rockville, Md.) said that partner GSK released results of a U.S. Phase I trial of SB-435495 demonstrating that the product decreased levels of Lp-PLA2. ...